OralTox Rapid Fluid 5 Panel Drug Test DOA simultaneous qualitative detection and differentiation

simultaneous qualitative detection and differentiation of influenza A and influenza B nucleoprotein antigens and SARS-CoV-2 nucleocapsid antigen directly from anterior nasal swab specimens of individuals with signs and symptoms of respiratory infection consistent with COVID-19 within the first five (5) days of symptom onset when tested at least twice over three days with at least 48 hours between tests

OralTox Advantages

Influenza A and Influenza B* Turnaround time: 30 minutes* Lab-quality accuracy* No maintenance or service contracts* Easy to run multiple patient tests simultaneously* EUA for use in CLIA-waived point-of-care settings* Accuracy: Influenza A: PPA 96

Detects 3 viruses at once (SARS-CoV-2

OralTox Rapid Fluid 5 Panel Drug Test DOA simultaneous qualitative detection and differentiationModel Drugs Included 5 Panel AMP, COC, METH, OPI, PCP OralTox is a FDA 510(k) cleared patented device that identifies the absence or presence of illicit drugs in minutes. Oral fluid drug testing offers a minimally invasive, observed collection to detect recent drug use with results in minutes. Using oral fluid, the collector can oversee a donor as he or she collects their own oral fluid specimens, reducing the likelihood of tampering or cheating as